antiquity
12-12-2002, 07:29 AM
Novel Compounds Drive the Market for Neuropathic Pain Therapies To $1.25 Billion by 2012, Reports WWMR, Inc.
SAN FRANCISCO, Dec. 12 /PRNewswire/ -- The current U.S. neuropathic pain market is worth an estimated $430 million. FDA-approved products to treat neuropathic pain are expected to be on the market by the end of 2003, some of which will be completely new to the market such as ziconotide by Elan, while others are currently marketed for other indications, such as depression or seizure disorders. By 2007, these and other new products are predicted to approximately double the size of the U.S. neuropathic pain market to $800 million.
Treatment for the management of neuropathic pain is one of the greatest challenges facing today's medical practice. Approximately 1% of the population (2.5 million people) in the United States suffers from moderate to severe neuropathic pain associated with back pain, diabetic neuropathy, complex regional pain syndrome, HIV/AIDS neuropathy, phantom limb pain, spinal cord injury, post-herpetic neuralgia, and trigeminal neuralgia. Research has identified more than 15 different mechanisms for neuropathic pain, which can be targeted by a wide variety of drug classes. There are more than 30 drugs that could be effective for the treatment of neuropathic pain in the development pipeline, which has grown significantly since 1999, when there were just 21 products.
Companies with leading or promising new approaches include Parke-Davis /
Pfizer with Neurontin, Wyeth-Ayerst with Effexor, Elan with ziconotide, Boehringer Ingelheim with meloxicam, and Endo Pharmaceuticals with lidocaine patch. Additional companies with currently marketed products or products in development for neuropathic pain include Abbott, Afferon, Allergan, AstraZeneca, Avanir Pharmaceuticals, Bio-Technology General Corporation, Cambridge Neuroscience, Cephalon, Curatek, Dainippon Pharmaceutical, Forest Laboratories, Genentech, GlaxoSmithKline, GroPep, GW Pharmaceuticals, Indevus Pharmaceuticals, Janssen, Kissei, Medtronic, Merz & Co., ML Laboratories, Neurobiological Technologies, Novartis, Novo Nordisk, Ortho-McNeil, Otsuka, Purdue-Frederick, Roche Laboratories, Sanofi-Synthelabo, Schering AG, Schwarz Pharma, Sepracor, Sibia Neurosciences, Takeda, and Vertex.
NEUROPATHIC PAIN is a newly released report from EP Publications, a service of WWMR, Inc., http://www.WWMR.com , evaluating the commercial outlook for pharmaceutical therapies to treat neuropathic pain from 2002 to 2012, identifying significant unmet needs for new products to treat neuropathic pain, examining the current challenges of the mechanisms of neuropathic pain, and reviewing promising targets for drug development. This report also provides detailed discussions of the epidemiology of eight types of neuropathic pain, including etiology and pathophysiology, diagnosis, as well as current therapies.
WWMR, Inc., is a leading marketing research and strategic consulting firm with global capabilities in the life sciences industry. Since 1994, WWMR, Inc. has provided over 450 high quality, insightful proprietary studies to clients in the pharmaceutical, biotech, medical device and diagnostic markets worldwide. WWMR, Inc., provides market opportunity and product assessments, competitive intelligence, forecasting, population projections, pre-launch product planning, post-launch product monitoring, product pricing strategy, database products, and on-site information center management.
SAN FRANCISCO, Dec. 12 /PRNewswire/ -- The current U.S. neuropathic pain market is worth an estimated $430 million. FDA-approved products to treat neuropathic pain are expected to be on the market by the end of 2003, some of which will be completely new to the market such as ziconotide by Elan, while others are currently marketed for other indications, such as depression or seizure disorders. By 2007, these and other new products are predicted to approximately double the size of the U.S. neuropathic pain market to $800 million.
Treatment for the management of neuropathic pain is one of the greatest challenges facing today's medical practice. Approximately 1% of the population (2.5 million people) in the United States suffers from moderate to severe neuropathic pain associated with back pain, diabetic neuropathy, complex regional pain syndrome, HIV/AIDS neuropathy, phantom limb pain, spinal cord injury, post-herpetic neuralgia, and trigeminal neuralgia. Research has identified more than 15 different mechanisms for neuropathic pain, which can be targeted by a wide variety of drug classes. There are more than 30 drugs that could be effective for the treatment of neuropathic pain in the development pipeline, which has grown significantly since 1999, when there were just 21 products.
Companies with leading or promising new approaches include Parke-Davis /
Pfizer with Neurontin, Wyeth-Ayerst with Effexor, Elan with ziconotide, Boehringer Ingelheim with meloxicam, and Endo Pharmaceuticals with lidocaine patch. Additional companies with currently marketed products or products in development for neuropathic pain include Abbott, Afferon, Allergan, AstraZeneca, Avanir Pharmaceuticals, Bio-Technology General Corporation, Cambridge Neuroscience, Cephalon, Curatek, Dainippon Pharmaceutical, Forest Laboratories, Genentech, GlaxoSmithKline, GroPep, GW Pharmaceuticals, Indevus Pharmaceuticals, Janssen, Kissei, Medtronic, Merz & Co., ML Laboratories, Neurobiological Technologies, Novartis, Novo Nordisk, Ortho-McNeil, Otsuka, Purdue-Frederick, Roche Laboratories, Sanofi-Synthelabo, Schering AG, Schwarz Pharma, Sepracor, Sibia Neurosciences, Takeda, and Vertex.
NEUROPATHIC PAIN is a newly released report from EP Publications, a service of WWMR, Inc., http://www.WWMR.com , evaluating the commercial outlook for pharmaceutical therapies to treat neuropathic pain from 2002 to 2012, identifying significant unmet needs for new products to treat neuropathic pain, examining the current challenges of the mechanisms of neuropathic pain, and reviewing promising targets for drug development. This report also provides detailed discussions of the epidemiology of eight types of neuropathic pain, including etiology and pathophysiology, diagnosis, as well as current therapies.
WWMR, Inc., is a leading marketing research and strategic consulting firm with global capabilities in the life sciences industry. Since 1994, WWMR, Inc. has provided over 450 high quality, insightful proprietary studies to clients in the pharmaceutical, biotech, medical device and diagnostic markets worldwide. WWMR, Inc., provides market opportunity and product assessments, competitive intelligence, forecasting, population projections, pre-launch product planning, post-launch product monitoring, product pricing strategy, database products, and on-site information center management.